Genomic and Precision Medicine: Oncology, Third Edition
Endometrial cancer
Publication
, Chapter
Spinosa, D; Montes de Oca, MK; Watson, CH; Berchuck, A; Previs, RA
January 1, 2022
The prior dichotomous classification of endometrial cancer into high and low risk subtypes based primarily on histology has been shown to be inadequate in predicting outcome and treatment response. More nuanced molecular categorization of these cancers provides improved targeted therapeutic options and a better understanding of the different disease processes.
Duke Scholars
DOI
ISBN
9780128006535
Publication Date
January 1, 2022
Start / End Page
191 / 203
Citation
APA
Chicago
ICMJE
MLA
NLM
Spinosa, D., Montes de Oca, M. K., Watson, C. H., Berchuck, A., & Previs, R. A. (2022). Endometrial cancer. In Genomic and Precision Medicine: Oncology, Third Edition (pp. 191–203). https://doi.org/10.1016/B978-0-12-800684-9.00014-9
Spinosa, D., M. K. Montes de Oca, C. H. Watson, A. Berchuck, and R. A. Previs. “Endometrial cancer.” In Genomic and Precision Medicine: Oncology, Third Edition, 191–203, 2022. https://doi.org/10.1016/B978-0-12-800684-9.00014-9.
Spinosa D, Montes de Oca MK, Watson CH, Berchuck A, Previs RA. Endometrial cancer. In: Genomic and Precision Medicine: Oncology, Third Edition. 2022. p. 191–203.
Spinosa, D., et al. “Endometrial cancer.” Genomic and Precision Medicine: Oncology, Third Edition, 2022, pp. 191–203. Scopus, doi:10.1016/B978-0-12-800684-9.00014-9.
Spinosa D, Montes de Oca MK, Watson CH, Berchuck A, Previs RA. Endometrial cancer. Genomic and Precision Medicine: Oncology, Third Edition. 2022. p. 191–203.
DOI
ISBN
9780128006535
Publication Date
January 1, 2022
Start / End Page
191 / 203